Conference Coverage

Change in approach advised for treatment-resistant depression


 

REPORTING FROM ANXIETY AND DEPRESSION CONFERENCE 2018

– Successfully treating patients who have treatment-resistant depression (TRD) means leaving acute intervention behind and adopting more chronic remediation techniques, Scott T. Aaronson, MD, said at the annual conference of the Anxiety and Depression Association of America.

“We need to change the paradigm; most of the research is looking at a 6- to 12-week outcome measure,” said Dr. Aaronson, director of the clinical research program at Sheppard Pratt Health System, Baltimore. “These are folks who have been depressed for most of their adult lives, and we don’t tend to take a longer-term perspective when looking at this.”

Treatment-resistant depression, Dr. Aaronson said, can be conceptualized as two levels. The first is failure of two agents or treatments, and the second is a failure of four or more agents – including electroconvulsive therapy. In light of those levels, Dr. Aaronson suggests approaching depression as one would cancer, with different stages of failure determining payment for more expensive treatments.

Dr. Scott T. Aaronson, director of clinical research at Sheppard Pratt Health System, Baltimore Courtesy Dr. Scott T. Aaronson

Before planning how best to handle treatment-resistant depression, it is important for psychiatrists to understand its complexity, and address the issues associated with current psychiatric diagnoses, Dr. Aaronson said.

Diagnoses now are based purely on phenomenological analysis rather than biological analysis, he said. “Basically, it’s a room full of people getting together to decide what the diagnostic criteria are,” Dr. Aaronson said. “It’s eminence-based medicine, not evidence-based medicine.”

This approach creates a large gray area in which diagnoses can fall, making it more difficult to distinguish between bipolar and unipolar depression, as well as tough to distinguish psychotic and nonpsychotic illnesses.

If a patient displayed mood instability, for example, but not enough to fit the criteria of bipolar disorder, this scenario would present a dilemma for psychiatrists unable to diagnose the patient as bipolar and unconvinced that it would help to treat the patient as only being depressed, according to an example from Dr. Aaronson.

Pages

Recommended Reading

Long-term effects of ketamine uncertain
MDedge Internal Medicine
Poor sleep, suicide risk linked in college students
MDedge Internal Medicine
Suicidal behaviors are associated with discordant sexual orientation in teens
MDedge Internal Medicine
Serotonin syndrome warnings magnify its rare probability
MDedge Internal Medicine
Serotonin syndrome risk with triptans and antidepressants ‘very low’
MDedge Internal Medicine
Insomnia, major depressive episode linked in U.S. soldiers
MDedge Internal Medicine
Depression risks identified in women
MDedge Internal Medicine
Consanguineous parentage raises risk of mood disorders, psychoses in offspring
MDedge Internal Medicine
Rosacea tied to physical and psychological comorbidities
MDedge Internal Medicine
Esketamine nasal spray brings fast relief of depressive symptoms
MDedge Internal Medicine